Volume 41 Supplement 1
Hypothyroxinemia in extremely low birth weight infants
© Ghirri et al. 2015
Published: 24 September 2015
Hypothyroxinemia of prematurity (HOP) is a transient alteration in thyroid hormone availabilityfound in more than half of extremely low birth weight infants (ELBW) born at less than 30 weeks . HOP is characterized by very low total T4 (TT4) and free T4 (FT4) levels with a normal or low thyroid stimulating hormone (TSH); TT4 and FT4 show a nadir at 7-10 days of life and they may remained low for the first 3-6 weeks of life depending from the severity of prematurity. The reason for this hypothyroxinemia is multifactorial including the loss of maternal transfer of T4, immaturity of the hypothalamic-pituitary-thyroid axis, limited thyroid capacity to increase synthesis and metabolism, immaturity of peripheral tissue deiodination, reduced iodine availability and excessive losses, drugs affecting thyroid function and other adverse perinatal events .
Thyroid hormones are critical for a normal maturation of the developing brain in the fetus and infant, including cerebral neurogenesis, neural migration and differentiation, axonal and dendritic growth and synaptogenesis, gliogenesis, myelogenesis[4, 5]. HOP has been associated with adverse neurodevelopmental outcomes such as deficits in developmental of motor, cognitive, language, memory, attention and it seem to be an independent risk factor for cognitive and behavioral deficits , however it is not clear the need to treat . In a large trial of prophylacticthyroxine treatment van Wassenaer et al. observed an 18-point improvement in mental development Bayley scores at 2 years postnatal age in infant born at less than 27 weeks gestation but, treated infants of more than 27 weeks had a 10-point deficit in Bayley scores. Overall there is insufficient evidence to determine whether use of thyroid hormones for treatment of preterm infants with transient hypothyroxinemia results in changes in neonatal morbidity and mortality, or reductions in neurodevelopmental impairments, but T4 supplementation may be beneficial in infants born at less than 27 weeks.
Recently Scratch et al. , contrary to expectations, reported that in children born at less than 30 weeks’ gestation, higher concentrations of free thyroxine over the first 6 weeks of life were associated with poorer cognitive function at 7 years of age. Future studies should be directed in understanding unexpected endocrine patterns after very preterm birth.
- La Gamma EF: Transient hypothyroxinemia of prematurity: 10 reports from our group. Semin Perinatol. 2008, 32: 377-446. 10.1053/j.semperi.2008.09.001.View ArticlePubMedGoogle Scholar
- Ogilvy-Stuart AL: Neonatal thyroid disorders. Arch Dis Child Fetal Neonatal Ed. 2002, 87: F165-F171. 10.1136/fn.87.3.F165.PubMed CentralView ArticlePubMedGoogle Scholar
- La Gamma EF, Paneth N: Clinical importance of hypothyroxinemia in the preterm infant and a discussion of treatment concerns. CurrOpinPediatr. 2012, 24: 172-180.Google Scholar
- Morreale de Escobar G, Obregon MJ, Escobar del Rey F: Role of thyroid hormone during early brain development. Eur J of Endocrinol. 2004, 151 (Suppl 3): U25-U37.View ArticleGoogle Scholar
- Scratch SE, Hunt RW, Thompson DK, et al: Free thyroxine levels after very preterm birth and neurodevelopmental outcomes at age 7 years. Pediatrics. 2014, 133: e 955-963. 10.1542/peds.2013-2425.View ArticleGoogle Scholar
- Kuban CK, Alfred EN, O'Shea TM, et al: An algoritm for identifying and classifying cerebral palsy in young children. J Pediatr. 2008, 153: 466-472. 10.1016/j.jpeds.2008.04.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Golombek SG, La Gamma EF, Paneth N: Treatment of transient hypothyroxinemia of prematurity: a survey of neonatal practice. J Perinatol. 2002, 22: 563-565. 10.1038/sj.jp.7210791.View ArticlePubMedGoogle Scholar
- Van Wassenaer AG, Kok JH, de Vijlder JJ, et al: Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks’ gestation. N Engl J Med. 1997, 336: 21-26. 10.1056/NEJM199701023360104.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.